Collective Molecular Activities of the Plant: Croton Tonkinensis
Example Image
PLANiTS DNA barcode
Taxonomic Information
Plant ID: NPO22879
Plant Latin Name: Croton Tonkinensis
Taxonomy Genus: Croton
Taxonomy Family: Euphorbiaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Compounds Summary
Overview of Ingredients
41 All known Ingredients in Total
Unique ingredients have been isolated from this plant.Plant-Ingredients Associations were manually curated from publications or collected from other databases.
38 Ingredients with Acceptable Bioavailablity
Unique ingredients exhibit acceptable human oral bioavailablity, according to the criteria of SwissADME [PMID: 28256516] and HobPre [PMID: 34991690]. The criteria details:SwissADME: six descriptors are used by SwissADME to evaluate the oral bioavailability of a natural product:
☑ LIPO(Lipophility): -0.7 < XLOGP3 < +5.0
☑ SIZE: 150g/mol < MW < 500g/mol
☑ POLAR(Polarity): 20Ų < TPSA < 130Ų
☑ INSOLU(Insolubility): -6 < Log S (ESOL) < 0
☑ INSATU(Insaturation): 0.25 < Fraction Csp3 < 1
☑ FLEX(Flexibility): 0 < Num. rotatable bonds < 9
If 6 descriptors of a natural plant satisfy the above rules, it will be labeled high HOB.
HobPre: A natural plant ingredient with HobPre score >0.5 is labeled high human oral availability (HOB)
33 Ingredients with experimental-derived Activity
Unique ingredients have activity data available.Ingredient Structrual Cards
Ingredient ID: NPC481536
Ingredient ID: NPC481535
Ingredient ID: NPC47853
Ingredient ID: NPC473336
Ingredient ID: NPC471475
Ingredient ID: NPC471046
Ingredient ID: NPC471045
Ingredient ID: NPC471044
Ingredient ID: NPC471042
Ingredient ID: NPC471041
Ingredient ID: NPC471040
Ingredient ID: NPC471039
Ingredient ID: NPC471038
Ingredient ID: NPC471037
Ingredient ID: NPC471036
Ingredient ID: NPC471035
Ingredient ID: NPC471034
Ingredient ID: NPC328901
Ingredient ID: NPC327336
Ingredient ID: NPC324777
Ingredient ID: NPC321560
Ingredient ID: NPC294259
Ingredient ID: NPC291320
Ingredient ID: NPC289148
Ingredient ID: NPC27243
Ingredient ID: NPC261012
Ingredient ID: NPC249235
Ingredient ID: NPC212661
Ingredient ID: NPC210214
Ingredient ID: NPC190704
Ingredient ID: NPC178684
Ingredient ID: NPC173158
Ingredient ID: NPC169848
Ingredient ID: NPC16911
Ingredient ID: NPC168575
Ingredient ID: NPC165895
Ingredient ID: NPC149761
Ingredient ID: NPC129909
Ingredient ID: NPC110780
Ingredient ID: NPC106078
Ingredient ID: NPC102292
Classification of Human Proteins Collectively Targeted by the Plant
*The classification criteria of Drug Transporter (DTP), CYP450 are referred to DrugMap. Other molecular targets in CMAUP are classified as therapeutic targets.
.
Detailed Information of Target Proteins
| Target Type | Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|---|
| Therapeutic Target | Isomerase | TOP1 | DNA topoisomerase I | P11387 | CHEMBL1781 |
| Therapeutic Target | Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Therapeutic Target | Methyl-lysine/arginine binding protein | SMN1 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Therapeutic Target | Phosphodiesterase | TDP2 | Tyrosyl-DNA phosphodiesterase 2 | O95551 | CHEMBL2169736 |
| Therapeutic Target | Phosphodiesterase | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Therapeutic Target | Protein Kinase | CHEK1 | Serine/threonine-protein kinase Chk1 | O14757 | CHEMBL4630 |
| Therapeutic Target | Protein Kinase | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Therapeutic Target | Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Therapeutic Target | Secreted protein | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
| Therapeutic Target | Secreted protein | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Therapeutic Target | Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Therapeutic Target | Structural protein | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Therapeutic Target | Transcription factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Therapeutic Target | Transcription factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Therapeutic Target | Unclassified protein | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
| Therapeutic Target | Unclassified protein | GMNN | Geminin | O75496 | CHEMBL1293278 |
Clinical Trials Summary
Overview
Clinical trials associated with plant from natural product (NP) & plant level:
| Clinical trials type | Number of clinical trials | |
|---|---|---|
 NP level | 886 | |
Clinical trial details
| NCT ID | Title | Condition | Form in clinical use | Associated by plant or compound |
|---|---|---|---|---|
| NCT01885013 | Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02483247 | A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00787527 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00797472 | Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01655693 | Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02445404 | Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01332968 | A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04968106 | Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00635193 | Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01541332 | Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT05113251 | Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05018520 | The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00878254 | Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04650984 | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03517449 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | endometrial neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT04498793 | Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00087178 | Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT04877275 | ATG-010(Selinexor) in Combination With Chemotherapy in RRMM | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00600977 | Liposomal Anthracyclin in the Treatment of Elderly ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00634205 | Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma | mesothelioma | Doxorubicin (NPC261012) | NP level |
| NCT03023358 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00201708 | Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03542266 | CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00379574 | Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01110603 | A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1) | cancer | Doxorubicin (NPC261012) | NP level |
| NCT01861951 | A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00507962 | Cisplatin HAI Study in Patients With Advanced Cancer and Dominant Liver Involvement | cancer | Doxorubicin (NPC261012) | NP level |
| NCT01324076 | Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT03539328 | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01831505 | Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01004991 | Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03399747 | Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00440726 | Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT03467178 | Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer. | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00193115 | Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00026208 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04745949 | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT00004031 | SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05404945 | Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02566993 | Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00203372 | Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01650701 | A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03017326 | Paediatric Hepatic International Tumour Trial | Hepatoblastoma | Doxorubicin (NPC261012) | NP level |
| NCT00886028 | Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | malignant pleural mesothelioma | Doxorubicin (NPC261012) | NP level |
| NCT00431795 | Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03553537 | Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03036488 | Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00174655 | BIG 02/98 Docetaxel - Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT04664972 | The TP Regimen in the Treatment of Early Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00628251 | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02822157 | Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer | malignant epithelial tumor of ovary | Doxorubicin (NPC261012) | NP level |
| NCT00041132 | S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | mature T-cell and NK-cell non-Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00815945 | Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors | carcinosarcoma;leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00590785 | Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04679064 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00907348 | Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00129376 | Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00299182 | Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02723994 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01451515 | NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00669773 | Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04159818 | Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01804127 | Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01139359 | Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04776525 | Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00083226 | Doxorubicin and Bortezomib in Treating Patients With Liver Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00017160 | Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT05386524 | Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT05303792 | Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00022945 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03042819 | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00974324 | Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02053597 | TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01847001 | Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01851733 | MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme | glioblastoma multiforme | Doxorubicin (NPC261012) | NP level |
| NCT03285607 | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03553238 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01649856 | A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00366106 | Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01809379 | Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | glioblastoma multiforme | Doxorubicin (NPC261012) | NP level |
| NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02978495 | Neoadjuvant Carboplatin in Triple Negative Breast Cancer | Hereditary breast and ovarian cancer syndrome | Doxorubicin (NPC261012) | NP level |
| NCT04083963 | Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00887536 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03719430 | APX005M and Doxorubicin in Advanced Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT05093920 | Role of DEB-TACE Versus c-TACE in Treatment of HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00049595 | Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03571308 | A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01040871 | Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01000285 | EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | acute leukemia of ambiguous lineage;acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03412643 | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03059615 | A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS | acute myeloid leukemia;myelodysplastic syndrome | Doxorubicin (NPC261012) | NP level |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00003595 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00944047 | Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00465673 | Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003421 | Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00580333 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05428670 | The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT02677116 | A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer | metastasis | Doxorubicin (NPC261012) | NP level |
| NCT00204646 | Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS) | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT03317457 | Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03485118 | RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00355199 | Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04164368 | Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00290732 | Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00189553 | Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse | fallopian tube cancer;ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00217425 | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
| NCT03994107 | Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01887587 | Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00003784 | S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04566887 | Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00925821 | Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01100372 | Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
| NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00248248 | DOXIL for Consolidation Therapy in Ovarian Cancer. | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT04224337 | Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma | non-small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00005867 | Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | inflammatory breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04895358 | 9-ING-41 in Patients With Advanced Cancers | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
| NCT03698227 | OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00930605 | The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02890602 | Erythropoietin for Management of Anemia Caused by Chemotherapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03425656 | Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01547741 | Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00209209 | Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01390584 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00703170 | Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00429299 | Wkly Taxol x 12 | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00543829 | Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02299999 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01746238 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02471820 | Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00136565 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01468740 | Prospective Study on HIV-related Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00003907 | Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies. | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01090128 | Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03056001 | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01705691 | Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03952572 | Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
| NCT03003520 | A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05058404 | Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00798252 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | cancer | Doxorubicin (NPC261012) | NP level |
| NCT01281943 | Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00101101 | Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01227941 | MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01328236 | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia | plasma cell leukemia;multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04263584 | Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00005800 | Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00439296 | ABT-751 With Chemotherapy for Relapsed Pediatric ALL | childhood acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | fallopian tube cancer;ovarian cancer;peritoneum cancer | Doxorubicin (NPC261012) | NP level |
| NCT04139304 | A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04199026 | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02529852 | A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03145558 | TATE Versus TACE in Intermediate Stage HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03805022 | Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT02527772 | Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00814541 | PAD. ICORG 05-01, V11 | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT04038489 | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04884035 | Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03023046 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02753881 | Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT03101748 | Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04996160 | Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT02449278 | The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01210768 | A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00211185 | A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00990860 | Study in Asia of the Combination of TACE With Sorafenib in HCC Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04535713 | GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03384654 | A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01172223 | Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00401635 | END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin | endometrial cancer | Doxorubicin (NPC261012) | NP level |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01404936 | Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00102609 | A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT05051891 | A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01498588 | Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04780464 | A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01622439 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01925612 | Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study | anaplastic large cell lymphoma;angioimmunoblastic T-cell lymphoma;unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01270373 | NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03596281 | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00722293 | A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02951728 | Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00003853 | 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00970385 | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04077905 | Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis. | hemophagocytic syndrome | Doxorubicin (NPC261012) | NP level |
| NCT01177683 | Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00809341 | R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01666444 | VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | fallopian tube cancer;ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT05075460 | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01004978 | Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02326025 | A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02098343 | p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT05453500 | Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT04322318 | A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | kidney Wilms tumor | Doxorubicin (NPC261012) | NP level |
| NCT01060904 | A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00550771 | German Preoperative Adriamycin Docetaxel Study | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00777673 | Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery. | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00659178 | Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00394251 | Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05112536 | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04874311 | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03515200 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT02505269 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00136435 | A Study in Adults With Untreated Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02858258 | ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03517137 | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00854568 | Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00780039 | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625) | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00878800 | A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03301350 | Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00502411 | Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01788137 | A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01705158 | Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00038610 | Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00758732 | Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00135135 | Therapy for Children With Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03712202 | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00265018 | HD10 for Early Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00184002 | Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04908787 | A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00976911 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00191789 | Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00789581 | A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01966133 | TACE as an Adjuvant Therapy After Hepatectomy for HCC | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01920932 | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04757337 | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT04231448 | Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05189197 | A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03609047 | Adjuvant Palbociclib in Elderly Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT05448820 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02255110 | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00451178 | A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03786783 | Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | ganglioneuroblastoma;neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT00082095 | To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02792491 | Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03192644 | The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial. | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00861120 | Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04980222 | A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01818063 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00093444 | Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT02406092 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00559845 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00225173 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02398240 | Brentuximab for Newly Diagnosed Hodgkin Disease | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03188198 | Risk Adapted Therapy in Diffuse Large B Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00206518 | Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02506777 | Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00054665 | PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT02298283 | Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03197935 | A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01008150 | Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003215 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT04227990 | Plinabulin iv Solution in Prevention of TAC Induced Neutropenia | neutropenia | Doxorubicin (NPC261012) | NP level |
| NCT01857934 | Therapy for Children With Advanced Stage Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT02995772 | Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00859495 | Trimodal Lung-Sparing Treatment of Pleural Mesothelioma | mesothelioma | Doxorubicin (NPC261012) | NP level |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2 | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03018626 | R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00945724 | Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04024462 | A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03233347 | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00165178 | Treatment of Acute Lymphoblastic Leukemia in Children | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00443677 | Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00801281 | First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. | chronic lymphocytic leukemia;follicular lymphoma;lymphoplasmacytic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05498896 | Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02472353 | Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02659930 | Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01204801 | Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03108300 | Use of Propranolol Hydrochloride in the Treatment of Metastatic STS | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01251107 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01388621 | Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT02421588 | Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04203641 | L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00448266 | Intensified IAA With PBPC Support in Breast Tumors With Evidence of a HRD | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01796002 | Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00822120 | S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00688740 | Docetaxel in Node Positive Adjuvant Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01746173 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | T-cell non-Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04887961 | Reprab Study: PLD + Trabectedin Rechallenge | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT03725059 | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00721747 | Taxotere®, Followed by Myocet® and Cyclophosphamide First Line Treatment in HER2 Neg Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02617485 | MabionCD20® Compared to MabThera® in Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03335241 | Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00461344 | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer | breast ductal carcinoma in situ | Doxorubicin (NPC261012) | NP level |
| NCT01840592 | Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00186888 | Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma | retinoblastoma | Doxorubicin (NPC261012) | NP level |
| NCT00542191 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00268853 | A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02997358 | Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT05006664 | Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02605915 | Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003541 | Combination Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02177695 | S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT01796197 | Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02451943 | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00568464 | Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03595592 | Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00121992 | Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02918747 | PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01712490 | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01186328 | EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01852435 | R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02428751 | R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00791947 | A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00003352 | Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01321008 | Stage I/II Nasal NK Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01812369 | Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT01966471 | A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00254592 | Neoadjuvant Treatment of Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00064116 | Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02427620 | Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00094497 | Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) | carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00189137 | Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT02670317 | Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00129389 | FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01669239 | Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00581360 | Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck | adenoid cystic carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02063022 | Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02897700 | A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03742986 | Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00949325 | Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01358071 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00083538 | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT01120171 | Myocet Plus Endoxan for Older Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05210374 | Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03283696 | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02414568 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00093795 | Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04243616 | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00052936 | Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02903004 | Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00346229 | Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00499122 | NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00563953 | Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03437070 | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00002318 | A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01329627 | Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003150 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04540692 | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02889523 | Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01455532 | A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00808639 | Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT02633137 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04293393 | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00796120 | An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01009970 | Study With Rituximab, Cyclophosphamide, Doxorubicin Liposomal (Myocet®), Vincristine, Prednisone, (R-COMP) to Treat Non-Hodgkin's Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00920153 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00841945 | Treatment of Aggressive Localized Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03758989 | A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02661503 | HD21 for Advanced Stages | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02772822 | A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00256243 | Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02275598 | Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00784537 | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01858207 | Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01459887 | Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05099666 | Lurbinectedin + Doxorubicin In Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01116635 | Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02449252 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01319981 | Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT02431559 | Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00626704 | Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00186849 | Therapy for Children With Advanced Stage High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT03294577 | Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia | neutropenia | Doxorubicin (NPC261012) | NP level |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | acute myeloid leukemia;acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00913835 | A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01046825 | Mature B-Cell Lymphoma And Leukemia Study III | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02362165 | CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02787239 | Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT00525642 | Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT03949634 | Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00849472 | A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00524810 | Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03340376 | Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer | cervical cancer | Doxorubicin (NPC261012) | NP level |
| NCT01272557 | Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial | carcinoma of liver and intrahepatic biliary tract | Doxorubicin (NPC261012) | NP level |
| NCT00174707 | Study of Docetaxel in Breast Cancer Patients | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT04859465 | Albumin-bound Paclitaxel Combined With Liposomal Doxorubicin in the Treatment of Advanced or Unresectable Angiosarcoma | angiosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02812654 | Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03071926 | Metronomic PLD in Patients With Primary Endocrine Resistant ABC | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00471965 | Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03493854 | A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00001498 | A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05467670 | Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00169130 | ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00126243 | Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma | Lymphoma, AIDS-Related | Doxorubicin (NPC261012) | NP level |
| NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00634179 | A Phase I/II Trial of VR-CHOP in Lymphoma Patients | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00801580 | My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia | lymphoid leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00324467 | Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | neoplasm of mature B-cells;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00866749 | Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma | lymphoid leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00002105 | Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02855359 | Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma | diffuse large B-cell lymphoma;follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02448537 | A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01358747 | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With AA Stage 3-4 or 2B HL | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03497702 | Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02412670 | Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer | urothelial carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00179725 | Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04307576 | A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01871766 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | rhabdomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01959490 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00691236 | Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00574236 | Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00326456 | MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00506155 | Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT05207514 | Compare the Efficacy and the Safety of Doxorubicin and Cyclophosphamide Followed by Taxotere Versus Doxorubicin and Cyclophosphamide Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00988195 | Study of Pegylated Human Recombinant Arginase for Liver Cancer | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00893516 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02938442 | Vaccination of Triple Negative Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02850419 | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01014767 | Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors | brain cancer;choroid plexus neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01176799 | Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00136539 | Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01974440 | A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00319865 | PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT02132949 | A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01998906 | A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00582725 | R-CHOP + GM-CSF for Previously Untreated LCL in Elderly | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01839097 | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00549848 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00577629 | Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00890656 | Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00072007 | Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01056679 | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01605526 | A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00591851 | Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00968253 | RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01854255 | Intraperitoneal Aerosol Chemotherapy in Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
| NCT03248427 | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01964391 | A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00336791 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT00877071 | LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03678883 | 9-ING-41 in Patients With Advanced Cancers | lung neoplasm;Malignant Bone Neoplasm;malignant glioma;metastasis;kidney cancer;sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02261805 | A Phase I/II Study of Ganetespib in Combination With Doxorubicin | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04101812 | Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer | urinary bladder cancer | Doxorubicin (NPC261012) | NP level |
| NCT03349281 | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT05218499 | Brightline-1: A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma | dedifferentiated liposarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00001339 | A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection | carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01935492 | 8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00755261 | Phase II Study of Doxorubicin and Avastin® in Sarcoma. | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00133302 | Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01784120 | A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04685616 | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR) | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00003165 | Doxorubicin in Treating Women With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003389 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03933319 | Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05389423 | Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas | Burkitts lymphoma;diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02377752 | A Study of Olaratumab in Japanese Participants With Advanced Cancer | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01490047 | Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02494713 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
| NCT01100944 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | Thymic Carcinoma;Thymoma | Doxorubicin (NPC261012) | NP level |
| NCT00450385 | Genes in Predicting Outcome of Patients With DLBCL Treated With Rituximab and Combination Chemotherapy (R-CHOP) | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04221035 | High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT02054559 | R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01678664 | Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors | neuroendocrine neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00361621 | Ph II CHOP+Velcade in Mediastinal LBCL | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02845882 | LBL-2016 for Children or Adolescents in China | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors | anaplastic astrocytoma;glioblastoma multiforme;oligoastrocytoma;oligodendroglioma;optic nerve glioblastoma;pilocytic astrocytoma | Doxorubicin (NPC261012) | NP level |
| NCT00278109 | Partial Breast Irradiation With Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00060346 | Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00183742 | Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | breast carcinoma in situ | Doxorubicin (NPC261012) | NP level |
| NCT03274492 | A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00102219 | A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04047004 | Adjuvant PIPAC in Gastric Cancer Patients | gastric adenocarcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01659099 | GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00194753 | Adjuvant Therapy for High-Risk Breast Cancer With Wkly Adriamycin & Oral Cytoxan With G-CSF for 12 Wks | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00719472 | A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03643276 | Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00483509 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung Carcinoma | small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00734877 | UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT02790580 | Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00484432 | Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00581776 | Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT01279291 | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer | Fallopian Tube Carcinoma;ovarian neoplasm;peritoneal neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02838225 | DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00455533 | Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00819221 | AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT03880695 | Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00265031 | HD12 for Advanced Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00691912 | Therapy of Metastatic Breast Cancer With Paclitaxel and Liposomal Doxorubicin | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00574587 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01148628 | Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01118026 | Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00314977 | Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer. | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00051311 | Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers | hematopoietic and lymphoid cell neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
| NCT00718484 | A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT02861222 | Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma | malignant glioma | Doxorubicin (NPC261012) | NP level |
| NCT04243434 | PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | Abnormality of blood and blood-forming tissues | Doxorubicin (NPC261012) | NP level |
| NCT00108953 | A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00002707 | Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01227408 | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP | angioimmunoblastic T-cell lymphoma;extranodal nasal NK/T cell lymphoma;unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00808899 | Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT05406401 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00687440 | Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01670500 | Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00365417 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer | endometrial cancer | Doxorubicin (NPC261012) | NP level |
| NCT00871013 | Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT04661007 | To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer | gastric cancer | Doxorubicin (NPC261012) | NP level |
| NCT05456022 | Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line | mouth neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00850512 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00148681 | Preoperative Herceptin and Navelbine for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | non-small cell lung carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00123929 | Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01855750 | A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02631109 | L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis | hemophagocytic syndrome | Doxorubicin (NPC261012) | NP level |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00546156 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02771743 | Response-based Treatment of High-risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT03699449 | An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00793377 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01992653 | A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02107378 | Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma | ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03023124 | Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | Castleman disease;diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01637532 | Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00486759 | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | neoplasm of mature B-cells | Doxorubicin (NPC261012) | NP level |
| NCT00140595 | ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00030381 | Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis | primary systemic amyloidosis | Doxorubicin (NPC261012) | NP level |
| NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01969032 | Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04584112 | A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer | triple-negative breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03755804 | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00408408 | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02247869 | Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01622361 | Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT02732015 | Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02215876 | Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00005584 | Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00434031 | CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01016054 | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT04043494 | International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma | lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01865110 | R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02475772 | A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01476787 | Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00124956 | Doxorubicin Pharmacokinetic (PK) Study | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00816959 | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | angioimmunoblastic T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00212082 | Gene Expression Profiles in Predicting Chemotherapy Response in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01104298 | Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00365365 | Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00426127 | Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00479128 | Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors | urethra cancer | Doxorubicin (NPC261012) | NP level |
| NCT00290498 | Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01354522 | TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00003578 | High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00613457 | Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00003782 | Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph Nodes | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | B-cell acute lymphoblastic leukemia;lymphoblastic lymphoma;T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01206881 | Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00002557 | Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01969578 | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | salivary gland cancer | Doxorubicin (NPC261012) | NP level |
| NCT04660799 | A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00476190 | ALL Adult Consortium Trial: Adult ALL Trial | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00312208 | Docetaxel in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT03937830 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01027910 | PCI-24781 in Combination With Doxorubicin to Treat Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT04172259 | ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00523380 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01185964 | A Study of Olaratumab in Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) | Cutaneous T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01415765 | MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01516580 | Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients | leukemia;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00303108 | Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02012088 | Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03004287 | 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00586846 | Phase II Study of Chemotherapy and Pamidronate for the Treatment of Newly Diagnosed Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03617432 | Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00109837 | S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | leukemia | Doxorubicin (NPC261012) | NP level |
| NCT04021992 | GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01324180 | Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01702129 | Anti-EGFR Immunoliposomes in Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00002565 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00131027 | High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL) | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00258960 | Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00083915 | DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00165087 | Treatment of Childhood Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00118209 | Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00923936 | Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | Kaposi's sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01396655 | PET in Breast Cancer Receiving Neoadjuvant Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03164993 | Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03329378 | Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00536393 | Treatment of Disseminated High Grade Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01527422 | Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01100359 | Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer | endometrial cancer | Doxorubicin (NPC261012) | NP level |
| NCT00493870 | TAC Versus TC for Adjuvant Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02116530 | Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy | Nausea and vomiting | Doxorubicin (NPC261012) | NP level |
| NCT05200312 | A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00903656 | Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01356680 | HD17 for Intermediate Stage Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02499367 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03536039 | RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00912444 | Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00145002 | A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) | adult T-cell leukemia/lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01523977 | Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT01990352 | Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01087424 | Mini-CHOP and Rituximab in Patients Aged Over 80 Years | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03804866 | NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT02131480 | Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma | leiomyosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02605694 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01258634 | A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response | osteosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00187161 | Treatment of Burkitt Lymphoma/Leukemia and B Large Cell NHL | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00883116 | A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer | endometrial cancer | Doxorubicin (NPC261012) | NP level |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00180908 | Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children | osteosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00446030 | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02560051 | Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer | prostate adenocarcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03201471 | Chidamide With R-CHOP Regimen for DLBCL Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00504504 | Rituximab and ABVD for Hodgkin's Patients | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02623972 | A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | inflammatory breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02710734 | Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) | urinary bladder carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02751918 | Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02622074 | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00575406 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02379585 | Fasting on Newly Diagnosed Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00869232 | UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT01440088 | A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01481194 | ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00169156 | A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma | angioimmunoblastic T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00006721 | S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00210379 | Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00530101 | The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00554164 | Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05234684 | A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03639246 | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT03802071 | A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01240629 | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | prostate cancer | Doxorubicin (NPC261012) | NP level |
| NCT01214668 | Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors | neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT05351346 | Genotype-guided Treatment in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00068393 | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | renal cell carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00201318 | A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00715208 | Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01864109 | Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00041210 | Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05346107 | PLD-cyclophosphamide-Nab-P Continuously Combined With Dual HER2 Blockage for HER2-positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00016406 | S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01415336 | AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | male breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00305084 | Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00204568 | Trofosfamide Versus Adriamycin in Elderly Patients With Soft Tissue Sarcoma (STS) | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT05371093 | Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma | follicular lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04546620 | Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01593020 | Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2 | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01889069 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05159193 | Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00795613 | Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01940497 | A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00512980 | PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01848132 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00323323 | CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00209222 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00001300 | A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00001384 | A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01569204 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04480099 | Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00779129 | A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01327521 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | hepatocellular carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02562378 | T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00083551 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00004067 | Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2 | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01882816 | Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer | thyroid cancer | Doxorubicin (NPC261012) | NP level |
| NCT03575520 | Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00144807 | ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Burkitts lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04012827 | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies | cutaneous melanoma;metastatic melanoma;non-small cell lung carcinoma;renal cell carcinoma;breast carcinoma;Fallopian Tube Carcinoma;ovarian carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT05088057 | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | fallopian tube cancer;ovarian cancer;peritoneal neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00450801 | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04835870 | Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00264953 | HD11 for Intermediate Stages | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02032277 | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04025593 | Biomarker Guided Treatment in DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02292979 | Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00004010 | Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03407144 | Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05097248 | Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03669783 | Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) | childhood kidney neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT03467373 | A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL | neoplasm of mature B-cells;non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03975205 | To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames | leukemia;lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02606305 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | fallopian tube cancer;ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT03678883 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00149214 | Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT05179733 | The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT05498259 | Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours | pancreatic ductal adenocarcinoma | Doxorubicin (NPC261012) | NP level |
| NCT03726879 | A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00608803 | Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00024102 | Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00038142 | Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients | Ewing sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03991884 | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia;lymphoblastic lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00060385 | Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02994251 | A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma | cholangiocarcinoma | Doxorubicin (NPC261012) | NP level |
| NCT01333423 | Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00147225 | AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | cancer | Doxorubicin (NPC261012) | NP level |
| NCT00956930 | Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT04348032 | Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01704716 | High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) | neuroblastoma | Doxorubicin (NPC261012) | NP level |
| NCT01148446 | R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00250874 | Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01220128 | Treatment With Pazopanib for Neoadjuvant Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01672671 | BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01309789 | A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms | anaplastic large cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04765228 | Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02449265 | Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00350948 | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer | ovarian neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT01009801 | Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer | liver cancer | Doxorubicin (NPC261012) | NP level |
| NCT02488564 | A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01783535 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | retinoblastoma | Doxorubicin (NPC261012) | NP level |
| NCT00288431 | Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015) | sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01779050 | Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | breast neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT00790244 | A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT02096588 | Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02784015 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT03650933 | A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00369681 | Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02783599 | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01168791 | Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01516567 | Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03161132 | Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT01379989 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer | ovarian cancer | Doxorubicin (NPC261012) | NP level |
| NCT00137111 | Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00671658 | Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00911183 | Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00266799 | The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer (P04445/MK-2746-071) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00135499 | R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02596971 | A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT03005015 | Lenvatinib in Second Line Endometrial Carcinoma | endometrial neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT02753647 | Chidamide Plus R-CHOP in Elderly DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00825149 | A Study of Obinutuzumab in Combination With Chemotherapy in Participants With CD20+ B-Cell Follicular Non-Hodgkin's Lymphoma | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00877006 | Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study | Mantle cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02285062 | Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02911142 | Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma | B-cell neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02125344 | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | inflammatory breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT04023916 | Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04301739 | to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03409198 | Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT01287741 | A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04478292 | A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy | Hepatoblastoma | Doxorubicin (NPC261012) | NP level |
| NCT01424982 | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Doxorubicin (NPC261012) | NP level |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | breast carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00145639 | Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma | osteosarcoma | Doxorubicin (NPC261012) | NP level |
| NCT05290090 | ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04569032 | A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | unspecified peripheral T-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04790903 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02181738 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00193037 | Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT00146562 | Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03618550 | Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT04624984 | PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | classic Hodgkin lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00609765 | Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors | pancreatic carcinoma | Doxorubicin (NPC261012) | NP level |
| NCT00931918 | Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients | diffuse large B-cell lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02055820 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL | non-Hodgkins lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | multiple myeloma | Doxorubicin (NPC261012) | NP level |
| NCT00484601 | Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma | nasopharyngeal neoplasm | Doxorubicin (NPC261012) | NP level |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT04032964 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | soft tissue sarcoma | Doxorubicin (NPC261012) | NP level |
| NCT00206466 | Biologic Correlative Taxotere/AC | breast cancer | Doxorubicin (NPC261012) | NP level |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | T-cell acute lymphoblastic leukemia | Doxorubicin (NPC261012) | NP level |
| NCT00770224 | S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma | lymphoma | Doxorubicin (NPC261012) | NP level |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | breast cancer | Doxorubicin (NPC261012) | NP level |
❱❱❱ Associated Human Diseases and Detailed Association Evidence
How do we define the Plant-Targeted Human Disease Association?
Associated human diseases of an individual plant are summurized based on FOUR types of association evidence, these include:
❶ Association by Therapeutic Target: Bioactive protein targets of the plant were defined in "Molecular Targets" section, target-disease associations collected from TTD database were subsequently used to build the associations between the plant and its targeted human diseases.
❷ Association by Disease Gene Reversion: Plant and a specific disease will be associated when >= 1 plant target gene overlaped with disease's DEGs.
❸ Association by Clinical Trials of Plant: Plant and a specific disease will be associated when >= 1 clinical trial (the plant is the intervetion) can be matched in ClinicalTrials.gov database.
❹ Association by Clinical Trials of Plant Ingredients: Plant and a specific disease will be associated when >= 1 clinical trial (the plant ingredient is the intervetion) can be matched in ClinicalTrials.gov database.
Associated Disease of the Plant |
Association Type & Detailed Evidence |
|---|---|
Diffuse large B-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
TOP2A
NCT00379574,NCT05422066,NCT05389423,NCT04824092,NCT01848132,NCT01804127,NCT03536039,NCT03129828,NCT01287741,NCT00582725,NCT03758989,NCT02753647,NCT01925612,NCT01087424,NCT04517435,NCT04263584,NCT00499018,NCT04594798,NCT04231448,NCT02285062,NCT04660799,NCT04025593,NCT01659099,NCT01622439,NCT01004991,NCT02889523,NCT05018520,NCT02951728,NCT04529772,NCT03943901,NCT04974996,NCT03274492,NCT00575406,NCT04546620,NCT00144807,NCT01009970,NCT00140595,NCT05189197,NCT01459887,NCT00850512,NCT00169130,NCT04002947,NCT02890602,NCT02054559,NCT04021992,NCT00268853,NCT02617485,NCT03201471,NCT01415765,NCT02596971,NCT04835870,NCT02449278,NCT02734771,NCT04139304,NCT02792491,NCT03399747,NCT03485118,NCT02428751,NCT02228512,NCT02867566,NCT00931918,NCT01148446,NCT00135499,NCT05290090,NCT05428670,NCT04023916,NCT05179733,NCT02531308,NCT04790903,NCT05498259,NCT01724021,NCT00355199,NCT05406401,NCT01285765,NCT03018626,NCT02772822,NCT03225924,NCT04661007,NCT04332822,NCT05234684,NCT01649856,NCT01852435,NCT05200312,NCT03003520,NCT05351346,NCT03650933,NCT02733380,NCT02855359,NCT02449265,NCT01040871 |
Liver cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12 |
AURKA,TOP2A,MTOR
NCT00956930,NCT01009801,NCT00003907,NCT02753881,NCT01324076,NCT00093444 |
Fallopian tube cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C74 |
TP53
NCT01666444,NCT00262990,NCT01100372,NCT02865811,NCT00003896,NCT00189553,NCT02606305,NCT00903630 |
Classical Hodgkin lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B30.1 |
NCT05008224,NCT03527628,NCT03004833,NCT02661503,NCT05404945,NCT04624984,NCT03712202,NCT03233347,NCT02414568
|
Neuroblastoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH85Z0 |
NCT00186849,NCT02771743,NCT04221035,NCT00578864,NCT00135135,NCT03786783,NCT01704716,NCT01857934,NCT00808899
|
Unspecified malignant neoplasms of unspecified sitesDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D4Z |
NCT00798252,NCT00608803,NCT00147225,NCT00305084,NCT00124956,NCT00703170,NCT01110603,NCT02483247,NCT00507962
|
HepatoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.01 |
HBB,GMNN,TOP2A,SSTR3,PMP22,CHEK1,AURKA
NCT03017326,NCT04478292 |
Malignant neoplasms of biliary tract, distal bile ductDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C15 |
GMNN,TOP2A,SSTR3,TP53,HIF1A,PMP22,CHEK1,AURKA,LMNA
|
Mature T-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90 |
HIF1A,TOP2A,CHEK1,MTOR,TOP1
NCT00265018,NCT00041210,NCT05075460,NCT00450801,NCT00002557,NCT04164368,NCT00854568,NCT03188198,NCT01490047,NCT00003421,NCT00004179,NCT00005867,NCT01974440,NCT00536393,NCT00052936,NCT02359162,NCT04980222,NCT05006664,NCT00118209,NCT00060346,NCT01516567,NCT00064116,NCT00003215,NCT00577993,NCT00433433,NCT02670317,NCT00101101,NCT01855750,NCT00003784,NCT00217425,NCT00290498,NCT01321008,NCT00003595,NCT00787527,NCT00006721,NCT02605694,NCT00049595,NCT03975205,NCT02529852,NCT03647072,NCT01527422,NCT00264953,NCT00577629,NCT00451178,NCT00003150,NCT01390584,NCT00003578,NCT01046825,NCT01992653,NCT00005584,NCT00004010,NCT00893516,NCT01831505,NCT00041132,NCT00299182,NCT00002565,NCT00211185,NCT00004112,NCT00003389,NCT00920153,NCT00004031,NCT00841945,NCT00945724,NCT01414855,NCT02918747,NCT02012088,NCT00770224,NCT00003541,NCT00369681,NCT00974324,NCT00554164,NCT01889069,NCT00822120,NCT00911183,NCT00210379,NCT04884035,NCT01139359,NCT00265031,NCT01118026,NCT00060385,NCT00504504,NCT00450385,NCT01404936 |
Solid tumour/cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00-2F9Z |
MTOR,TOP1,EPAS1,HIF1A,TP53,CHEK1,AURKA,TOP2A
|
NeoplasmsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 02 |
NCT03023124,NCT00819221,NCT02377752,NCT01148628,NCT01702129,NCT01455532,NCT01214668,NCT03617432
|
LeukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60-2B33 |
NCT00109837,NCT00038610,NCT02723994,NCT00613457,NCT03975205,NCT01319981,NCT00072007,NCT01516580
|
Adenocarcinoma of pancreasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.0 |
TOP1,DHCR7,PMP22,HIF1A,HTR2B,CHEK1,AURKA,LMNA
|
Mesothelioma of pleuraDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26.0 |
TOP1,DHCR7,GMNN,TOP2A,SSTR3,SMN1,AURKA,LMNA
|
LeiomyosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B58 |
NCT04996004,NCT00815945,NCT05099666,NCT03437070,NCT02997358,NCT03420014,NCT02131480
|
Brain cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00 |
TOP2A,EPAS1,HIF1A,TOP1,TP53
NCT01014767 |
Endometrial cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76 |
TP53,MTOR
NCT00883116,NCT01767155,NCT01100359,NCT00401635 |
Malignant neoplasms of bladder, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.Z |
NCT04101812,NCT00808639,NCT01812369,NCT00506155,NCT00635726,NCT02177695
|
Adenocarcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.0 |
GMNN,TOP2A,HTR2B,CHEK1,AURKA,THPO
|
Germ cell tumour of testisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C80.2 |
RAB9A,TOP1,GMNN,HIF1A,SMN1,CHEK1
|
Malignant neoplasms of adrenal glandDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D11 |
DHCR7,GMNN,TOP2A,SSTR3,CHEK1,AURKA
|
Ovarian cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73 |
TOP2A,TOP1,CHEK1,TP53
NCT00179725,NCT04729387,NCT00976911,NCT00523380,NCT02098343,NCT01113957,NCT00657878,NCT00326456,NCT04908787,NCT00758732,NCT03804866,NCT01637532,NCT03539328,NCT04679064,NCT01802749,NCT03467178,NCT00262990,NCT02431559,NCT00861120,NCT04348032,NCT00610792,NCT03699449,NCT05467670,NCT03596281,NCT04887961,NCT02475772,NCT01016054,NCT02606305,NCT00635193,NCT00189553,NCT01809379,NCT01388621,NCT01100372,NCT03335241,NCT01227941,NCT00903630,NCT03161132,NCT01696032,NCT01666444,NCT02421588,NCT00722592,NCT01358071,NCT03639246,NCT00484432,NCT01705158,NCT01379989,NCT02865811,NCT00003896 |
Malignant haematopoietic neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33 |
TP53,TOP2A,AURKA,MTOR
NCT00051311 |
Lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
CHEK1,TOP2A,AURKA,TOP1,MTOR
|
Renal cell carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
EPAS1,TOP1,MTOR
NCT02419495,NCT00068393 |
Kaposi sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B57 |
TOP2A
NCT00002318,NCT00002105,NCT00923936,NCT02659930 |
Acute myeloid leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A60 |
AURKA,TP53,TOP2A
NCT03059615,NCT03860844 |
Prostate cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82 |
AURKA,MTOR
NCT02494713,NCT01240629,NCT00176293 |
OsteosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B51 |
NCT00145639,NCT01258634,NCT00691236,NCT00586846,NCT00180908
|
Carcinomas of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.0 |
NCT03542669,NCT03598270,NCT02107378,NCT02419495,NCT00312650
|
Malignant neoplasms of corpus uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.Z |
TOP2A,CHEK1,AURKA
NCT03005015,NCT03517449 |
Carcinosarcoma of uterusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.43 |
TOP1,DHCR7,GMNN,TOP2A,TP53
|
Pancreatic cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10 |
MTOR,CHEK1,TOP2A,TP53
|
Pleural mesotheliomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C26 |
MTOR
NCT00859495,NCT00886028,NCT00634205 |
Ewing sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B52 |
NCT00038142,NCT02063022,NCT01864109,NCT00568464
|
Neuroendocrine carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C34 |
NCT00183742,NCT01678664,NCT00001339,NCT00094497
|
Malignant neoplasms of retroperitoneumDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C50 |
NCT01100372,NCT00003896,NCT00903630,NCT02865811
|
Adult T-cell lymphoma or leukaemia, human T-cell lymphotropic virus type 1-associatedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.5 |
NCT01000285,NCT03007147,NCT02228772,NCT01788137
|
Burkitt lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH4KA9 |
NCT05270057,NCT00669877,NCT05389423,NCT00126191
|
Malignant neoplasms of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72 |
HBB
NCT01854255,NCT04358341,NCT05318794 |
Neoplasms of unknown behaviour of urinary organsDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F98 |
NCT03669783,NCT04383743,NCT02710734,NCT04506554
|
Angioimmunoblastic T-cell lymphomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH1J86 |
NCT03853044,NCT00725231,NCT01719835,NCT00169156
|
Adenocarcinoma of stomachDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72.0 |
AURKA,CHEK1,TOP2A
NCT04047004 |
Serous cystadenoma,borderline malignancy of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.4 |
GMNN,TP53,CHEK1,AURKA
|
Squamous cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.2 |
GMNN,TOP2A,CHEK1,AURKA
|
Urothelial carcinoma of bladderDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.2 |
DHCR7,TOP2A,CHEK1,AURKA
|
Invasive carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C61 |
TOP2A,CHEK1,AURKA,THPO
|
Precursor cell lymphoblastic leukaemia, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH5J37 |
NCT01523977,NCT00440726,NCT00439296,NCT01887587,NCT02420717,NCT00890656,NCT03023046,NCT03571321,NCT00973752,NCT00671658,NCT04307576,NCT03384654,NCT03553238,NCT03515200,NCT00600977,NCT03349281,NCT00165087,NCT01186328,NCT03991884,NCT00187161,NCT00131027,NCT03643276,NCT00165178,NCT04996160,NCT03020030,NCT01324180,NCT02881086,NCT03150693,NCT05303792,NCT02419755,NCT03860844,NCT00476190,NCT03117751,NCT03817320,NCT00968253,NCT00136435,NCT05453500,NCT00137111,NCT00549848
|
Multiple myelomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A83 |
MTOR
NCT01328236,NCT00574080,NCT00814541,NCT01215344,NCT01548573,NCT00319865,NCT04877275,NCT00750815,NCT01481194,NCT01541332,NCT00366106,NCT00617591,NCT01070862,NCT00869232,NCT00215943,NCT01492881,NCT01101594,NCT01177683,NCT00572169,NCT01246063,NCT01078441,NCT03004287,NCT00871013,NCT00083551,NCT02186834,NCT00083538,NCT00083915,NCT00516191,NCT00003853,NCT02471820,NCT02362165,NCT00706953,NCT00148317,NCT00925821,NCT00734877,NCT00441168,NCT01394354 |
Hodgkin lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B30 |
CHEK1
NCT03159897,NCT01251107,NCT00816959,NCT03755804,NCT01358747,NCT00784537,NCT01652261,NCT04685616,NCT01920932,NCT03033914,NCT02505269,NCT00512980,NCT01712490,NCT00795613,NCT03407144,NCT02292979,NCT01056679,NCT02979522,NCT00443677,NCT00026208,NCT00225173,NCT01060904,NCT02398240,NCT00797472,NCT02181738,NCT03618550,NCT02247869,NCT02275598,NCT01468740,NCT00038558,NCT01569204,NCT02298283,NCT00736320,NCT03517137,NCT03646123,NCT04638790,NCT01356680 |
Soft tissue disorderDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FB56 |
NCT00017160,NCT04650984,NCT03108300,NCT03056001,NCT03719430,NCT00718484,NCT03042819,NCT05448820,NCT00790244,NCT03317457,NCT02049905,NCT00878800,NCT04032964,NCT01861951,NCT03283696,NCT05100628,NCT04910126,NCT04874311,NCT02783599,NCT01168791,NCT04780464,NCT04776525,NCT01440088,NCT04656262,NCT00502411,NCT00484341,NCT04765228,NCT00755261,NCT00626704,NCT03698227,NCT02784015,NCT02255110,NCT04012827,NCT02451943,NCT03805022,NCT00102609,NCT01514188,NCT04757337
|
Stomach cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B72 |
TP53,TOP1,TOP2A
|
Head and neck cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D42 |
MTOR,TP53,CHEK1
|
Pulmonary hypertensionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BB01 |
HIF1A,MTOR,HTR2B
|
Myelodysplastic syndromeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A37 |
TOP1,TP53
NCT03059615 |
Bladder cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94 |
TOP2A,TP53,MTOR
|
Colorectal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B91 |
TOP2A,TP53,TOP1
|
Peritoneal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C51 |
TP53
NCT00262990,NCT01279291 |
Rhabdomyosarcoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0GA1 |
NCT04625907,NCT04213794,NCT01871766
|
Non-small cell lung cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25 |
NCT04224337,NCT03808480,NCT02419495
|
Malignant neoplasm of pancreas, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C10.Z |
NCT04203641,NCT00609765,NCT00426127
|
Small cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.1 |
NCT00483509,NCT02261805,NCT02566993
|
Glioblastoma, primary, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0MB1 |
NCT00944801,NCT02372409,NCT01851733
|
Inflammatory carcinoma of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C62 |
NCT02876302,NCT02623972,NCT02125344
|
Other specified malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90.Y |
TOP2A,TOP2A
NCT04322318 |
Malignant neoplasm metastasis, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E2Z |
NCT03678883,NCT02419495,NCT02677116
|
Superficial ovarian endometriosisDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GA10.B4 |
PMP22,RAB9A,LMNA
|
Malignant neoplasms of oesophagusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B70 |
AURKA,CHEK1,TOP2A
|
Glioblastoma of brainDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.00 |
GMNN,RAB9A,LMNA
|
Renal cell carcinoma, chromophobe typeDisease Category: X.Extension CodesDisease ICD-11 Code: XH6153 |
DHCR7,TOP2A,AURKA
|
Carpal tunnel syndromeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C10.0 |
HBB,HTR2B,THPO
|
Pleomorphic sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B54 |
MTOR
NCT04968106,NCT04199026,NCT02326025,NCT01185964,NCT00288431,NCT02732015,NCT03678883,NCT00204646,NCT00001300,NCT01104298,NCT05210374,NCT02448537,NCT03802071,NCT00796120,NCT02812654,NCT01746238,NCT00949325,NCT01605526,NCT03880695,NCT00189137,NCT00204568,NCT04535713,NCT01027910 |
Hepatocellular carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH4W48 |
NCT01116635,NCT03145558,NCT02527772,NCT00057382,NCT01381211,NCT03192644,NCT00471965,NCT00990860,NCT03937830,NCT01281943,NCT01655693,NCT00108953,NCT00083226,NCT01858207,NCT01966133,NCT02958163,NCT01840592,NCT01327521,NCT01004978,NCT00877071,NCT05093920,NCT00988195
|
Malignant lymphoma, not elsewhere classifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33.5 |
NCT00133302,NCT00184002,NCT00324467,NCT01516580,NCT02406092,NCT03467373,NCT00719472,NCT05238064,NCT00825149,NCT00809341,NCT03571308,NCT02055820,NCT00323323,NCT02626455,NCT00201318,NCT01746173,NCT01777152,NCT01332968,NCT00193440,NCT00455897,NCT00361621,NCT01200758
|
Neoplasms of unknown behaviour of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2F95 |
NCT00550771,NCT02622074,NCT01220128,NCT00722293,NCT04895358,NCT00021255,NCT01779050,NCT00194753,NCT00174707,NCT00779129,NCT00543829,NCT00849472,NCT03036488,NCT00174655,NCT03678883,NCT00121992,NCT00525642,NCT00446030,NCT00429299,NCT00687440
|
Muscular atrophyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B61 |
SMN1,SMN2
|
Transplant rejectionDisease Category: 22.Injury, poisoning or certain other consequences of external causesDisease ICD-11 Code: NE84 |
TP53,MTOR
|
Cervical cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C77 |
TP53
NCT03340376 |
Esophageal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B70 |
TP53,TOP1
|
Bacterial infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A00-1C4Z |
TOP2A,TOP1
|
Adrenomedullary hyperfunctionDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A75 |
EPAS1,HIF1A
|
LiposarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B59 |
TP53
NCT05218499 |
Mature B-cell leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A82 |
TP53
NCT01328236 |
Malignant neoplasms of fallopian tube, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C74.Z |
NCT02419495,NCT01279291
|
NeutropeniaDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4B00 |
NCT04227990,NCT03294577
|
Glioma, malignantDisease Category: X.Extension CodesDisease ICD-11 Code: XH4RQ3 |
NCT03678883,NCT02861222
|
Lymphoid leukaemia, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH7Q12 |
NCT00866749,NCT00801580
|
Anaplastic large cell lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH1LC0 |
NCT01309789,NCT01719835
|
Primary haemophagocytic lymphohistiocytosisDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A01.23 |
NCT04077905,NCT02631109
|
RetinoblastomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D02.2 |
NCT00186888,NCT01783535
|
PheochromocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH3854 |
SSTR3,EPAS1
|
Osteoarthritis, unspecifiedDisease Category: 15.Diseases of the musculoskeletal system or connective tissueDisease ICD-11 Code: FA0Z |
HBB,TOP2A
|
Other specified malignant neoplasms of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.Y |
AURKA,TOP2A
|
Chikungunya virus diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D40 |
HIF1A,LMNA
|
Breast cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C60-2C6Y |
TOP2A,MTOR,TOP1,AURKA
NCT00087178,NCT03498716,NCT00303108,NCT01966471,NCT03197935,NCT01333423,NCT00559845,NCT00206518,NCT02605915,NCT00365365,NCT04293393,NCT00148681,NCT00944047,NCT02995772,NCT00003352,NCT03949634,NCT00004067,NCT00887536,NCT03595592,NCT02472353,NCT02506777,NCT00005800,NCT02032277,NCT00542191,NCT00669773,NCT01547741,NCT04159818,NCT00903656,NCT04664972,NCT01784120,NCT00193115,NCT00123929,NCT00499122,NCT02850419,NCT01008150,NCT00465673,NCT03575520,NCT01940497,NCT02790580,NCT01057069,NCT04038489,NCT05386524,NCT01206881,NCT00789581,NCT04762901,NCT00024102,NCT05346107,NCT01090128,NCT01705691,NCT04584112,NCT02488564,NCT00016406,NCT01998906,NCT05113251,NCT00486668,NCT00408408,NCT00002707,NCT05097248,NCT00365417,NCT00003782,NCT03726879,NCT00721747,NCT00434031,NCT03412643,NCT05112536,NCT02413320,NCT00312208,NCT00149214,NCT01796197,NCT00590785,NCT04301739,NCT00001498,NCT01396655,NCT00455533,NCT03409198,NCT01172223,NCT00001384,NCT03301350,NCT00193037,NCT05207514,NCT03285607,NCT00093795,NCT01415336,NCT01669239,NCT03493854,NCT00574587,NCT02641847,NCT00212082,NCT04243616,NCT04540692,NCT01672671,NCT01670500,NCT00206466,NCT00793377,NCT00563953,NCT02938442,NCT05088057,NCT04443348,NCT01847001,NCT01120171,NCT00691912,NCT01358877,NCT00258960,NCT01969032,NCT01818063,NCT00256243,NCT02299999,NCT00346229,NCT05275777,NCT01964391,NCT00524810,NCT00290732,NCT00146562,NCT00278109,NCT02215876,NCT00912444,NCT01270373,NCT00530101,NCT01646034,NCT04172259,NCT03742986,NCT05020860,NCT00129389,NCT01959490,NCT00136539,NCT02562378,NCT00431795,NCT00003165,NCT02897700,NCT00448266,NCT01131364,NCT00191789,NCT03425656,NCT00254592,NCT03933319,NCT04024462,NCT01176799,NCT00777673,NCT02132949,NCT00129376,NCT01204801,NCT00404066,NCT00636441,NCT04083963,NCT02499367,NCT01329627,NCT01227408,NCT00102219,NCT03725059,NCT00336791,NCT01210768,NCT01622361,NCT00546156,NCT05498896,NCT00394251,NCT03248427,NCT00574236,NCT02685657,NCT04498793,NCT03994107,NCT00203372,NCT03497702,NCT02379585,NCT00688740,NCT02053597,NCT00580333,NCT01990352,NCT00082095,NCT00201708,NCT03609047,NCT00314977,NCT03071926,NCT01354522,NCT00591851,NCT05159193,NCT00250874,NCT00266799,NCT01593020,NCT03329378,NCT02096588,NCT02838225,NCT00493870 |
Follicular lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A80 |
TOP2A
NCT01852435,NCT01476787,NCT00774826,NCT02889523,NCT00801281,NCT00634179,NCT05058404,NCT01650701,NCT04745832,NCT02449252,NCT05371093,NCT02855359,NCT00715208,NCT00907348,NCT00494780 |
Peripheral T-cell lymphoma, not otherwise specifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.C |
NCT01839097,NCT00791947,NCT00725231,NCT04569032,NCT03952572,NCT00970385,NCT00136565,NCT03023358,NCT03542266,NCT04922567,NCT01719835,NCT03553537,NCT01796002,NCT04480099,NCT00930605,NCT02445404
|
Mantle cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85.5 |
NCT00581776,NCT00209222,NCT00022945,NCT00401817,NCT02633137,NCT00477412,NCT05051891,NCT01865110,NCT00878254,NCT02427620,NCT00722137,NCT02858258,NCT00209209,NCT00877006,NCT04566887
|
Precursor B-lymphoblastic neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A70 |
NCT01887587,NCT00866749,NCT04043494,NCT03817320,NCT03564704,NCT03991884,NCT02881086,NCT03023046,NCT02228772,NCT02845882,NCT05303792,NCT01451515
|
Diffuse large B-cell lymphomasDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A81 |
EPAS1,GMNN,PMP22,TOP2A,SSTR3,TP53,SMN1,HTR2B,CHEK1,AURKA,THPO,LMNA
|
Mature B-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85 |
TOP2A,TOP1
NCT00324467,NCT04745949,NCT00054665,NCT02787239,NCT00486759,NCT03677141,NCT03467373,NCT05201248 |
Malignant neoplasms of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73 |
NCT00628251,NCT01279291,NCT02903004,NCT00350948,NCT01121406,NCT00780039,NCT00248248,NCT00913835,NCT02751918,NCT00659178
|
Breast in situ carcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E65 |
NCT01498588,NCT03164993,NCT01935492,NCT05177796,NCT01885013,NCT02419495,NCT03971409,NCT03101748,NCT01275677,NCT04081389
|
Hepatocellular carcinoma of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.02 |
GMNN,TOP2A,SSTR3,CHEK1,AURKA,GMNN,TOP2A,SSTR3,CHEK1,AURKA
|
Attention deficit hyperactivity disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A05 |
HTR2B
|
LymphangioleiomyomatosisDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CB07 |
MTOR
|
Myocardial infarctionDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BA41-BA43 |
THPO
|
Arteries/arterioles disorderDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BD52 |
MTOR
|
AsthmaDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA23 |
TOP2A
|
Chronic myelomonocytic leukaemiaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A40 |
MTOR
|
Anogenital wartsDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A95 |
TOP2A
|
Sickle-cell disorderDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3A51 |
HBB
|
Metastatic liver/bile duct neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D80 |
TP53
|
ThrombosisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB61-GB90 |
TOP2A
|
Ischaemic/haemorrhagic strokeDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B20 |
THPO
|
Common wartsDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1E80 |
TOP2A
|
Otitis externaDisease Category: 10.Diseases of the ear or mastoid processDisease ICD-11 Code: AA00-AA13 |
TOP2A
|
Respiratory system diseaseDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CB40-CB7Z |
TOP2A
|
Human immunodeficiency virus diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1C60-1C62 |
TOP1
|
Anal cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C00 |
CHEK1
|
ThalassaemiaDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3A50 |
HBB
|
Metastatic lymph node neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D60 |
MTOR
|
DepressionDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A70-6A7Z |
HTR2B
|
Multiple sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A40 |
TOP2A
|
Gastrointestinal stromal tumourDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B5B |
TOP1
|
Pain, unspecifiedDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MG3Z |
MTOR
|
Cushing syndromeDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A70 |
SSTR3
|
Kidney failureDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GB60-GB6Z |
TP53
|
Malignant mesenchymal neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B5D-2B5Y |
MTOR
|
HydrocephalusDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8D64 |
MTOR
|
HIV-infected patients with tuberculosisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1B10-1B14 |
TOP2A
|
Lip/oral cavity/pharynx neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6E |
TP53
|
PsoriasisDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EA90 |
TOP2A
|
Urinary tract infectionDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GC08 |
TOP2A
|
Otitis mediaDisease Category: 10.Diseases of the ear or mastoid processDisease ICD-11 Code: AA80-AB0Z |
TOP2A
|
Chronic arterial occlusive diseaseDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BD4Z |
TP53
|
Fungal infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F29-1F2F |
RAB9A
|
Pituitary gland disorderDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A60-5A61 |
HTR2B
|
Ovarian dysfunctionDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A80 |
TP53
|
Psychotic disorderDisease Category: 06.Mental, behavioural or neurodevelopmental disordersDisease ICD-11 Code: 6A20-6A25 |
HTR2B
|
Alzheimer diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A20 |
TOP2A
|
Gonococcal infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A70-1A7Z |
TOP2A
|
ChemoprotectionDisease Category: NADisease ICD-11 Code: N.A. |
TOP2A
|
Acute diabete complicationDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A2Y |
AURKA
|
SyphilisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1A61-1A6Z |
TOP2A
|
Other specified amyloidosisDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5D00.Y |
NCT00030381
|
Nausea/vomitingDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: MD90 |
NCT02116530
|
Castlemans diseaseDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4B2Y |
NCT02228512
|
Cutaneous T-cell lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH1951 |
NCT02192021
|
Urethral cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C93 |
NCT00479128
|
CholangiocarcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH7M15 |
NCT02994251
|
Mature B-cell neoplasms, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A8Z |
NCT02911142
|
Malignant mixed epithelial mesenchymal tumour of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B5D.0 |
NCT02822157
|
Hereditary breast and ovarian cancer syndromeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C65 |
NCT02978495
|
Adenocarcinoma of prostateDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C82.0 |
NCT02560051
|
AngiosarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B56 |
NCT04859465
|
Malignant neoplasm of liverDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C12.0 |
NCT01272557
|
Malignant neoplasms of kidney, except renal pelvisDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C90 |
NCT03678883
|
Malignant neoplasms of other or unspecified parts of mouthDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B66 |
NCT05456022
|
Melanoma of skin, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30.Z |
NCT02419495
|
Mixed tumour, malignant, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH0V86 |
NCT01969578
|
Malignant lymphoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH5FJ5 |
NCT00126243
|
Diseases of the blood or blood-forming organs, unspecifiedDisease Category: 03.Diseases of the blood or blood-forming organsDisease ICD-11 Code: 3C0Z |
NCT04243434
|
Ductal carcinoma in situ of breastDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E65.2 |
NCT00461344
|
Optic nerve disorderDisease Category: 09.Diseases of the visual systemDisease ICD-11 Code: 9C40 |
NCT02372409
|
OligoastrocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH6F49 |
NCT02372409
|
ThymomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
NCT01100944
|
Thymic carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH6AK2 |
NCT01100944
|
GanglioneuroblastomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH77W7 |
NCT03786783
|
Metastatic lung neoplasmDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D70 |
NCT03678883
|
Carcinosarcoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH2W45 |
NCT00815945
|
Astrocytoma, anaplasticDisease Category: X.Extension CodesDisease ICD-11 Code: XH96C7 |
NCT02372409
|
Chronic lymphocytic leukaemia or small lymphocytic lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A82.0 |
NCT00801281
|
Choroid plexus tumoursDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A00.22 |
NCT01014767
|
Carcinoma of male breastDisease Category: X.Extension CodesDisease ICD-11 Code: XH5KW8 |
NCT00470301
|
Acute leukaemias of ambiguous lineageDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A61 |
NCT02419755
|
Pilocytic astrocytomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH12D2 |
NCT02372409
|
Adenoid cystic carcinomaDisease Category: X.Extension CodesDisease ICD-11 Code: XH4302 |
NCT00581360
|
AdenocarcinomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D40 |
NCT04852367
|
Transitional cell carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH8EH1 |
NCT02412670
|
Chronic myelogenous leukaemia, BCR-ABL1-positiveDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A20.0 |
NCT01424982
|
Extranodal NK/T-cell lymphoma, nasal typeDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90.6 |
NCT00725231
|
Burkitt-like lymphoma with 11q aberrationDisease Category: X.Extension CodesDisease ICD-11 Code: XH8NN2 |
NCT02228772
|
Thyroid cancerDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D10 |
NCT01882816
|
Malignant neoplasm metastasis in bone or bone marrowDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2E03 |
NCT03678883
|
Malignant neoplasms of nasopharynxDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B6B |
NCT00484601
|
Lymphoplasmacytic lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A85.4 |
NCT00801281
|
Oligodendroglioma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH7W59 |
NCT02372409
|
Adult T-cell leukaemia/lymphoma (HTLV-1 positive)Disease Category: X.Extension CodesDisease ICD-11 Code: XH6TE2 |
NCT00145002
|
Non-alcoholic steatohepatitisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB92.1 |
HBB
|
Hypertrophic cardiomyopathyDisease Category: 11.Diseases of the circulatory systemDisease ICD-11 Code: BC43.1 |
HBB
|
LeishmaniasisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F54 |
SSTR3
|
Malignant neoplasm metastasis in lymph nodes of head, face or neckDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D60.0 |
AURKA
|
Non-alcoholic fatty liver diseaseDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB92 |
HBB
|
Myotonic dystrophyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C71.0 |
TOP2A
|
Melanoma of skinDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C30 |
SSTR3
|
Cytomegaloviral diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D82 |
THPO
|
Systemic lupus erythematosusDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A40.0 |
EPAS1
|
Malignant neoplasms of thyroid gland, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2D10.Z |
SSTR3
|
Malignant neoplasms of thymusDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C27 |
GMNN
|
Lyme borreliosisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1C1G |
HBB
|
❱❱❱ Network Visualization of Plant-Targeted Human Disease Associations
Plant-Targeted Human Disease Network
>> Targets derived from weak experimental activities
